Coupe M O, Anderson J V, Morris J A, Alstead E M, Bloom S R, Hodgson H J
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Aliment Pharmacol Ther. 1988 Apr;2(2):167-72. doi: 10.1111/j.1365-2036.1988.tb00684.x.
Therapy for diarrhoea associated with the carcinoid syndrome is often unsatisfactory. In an open study ICS 205-930 (Sandoz Limited), a novel 5HT3-antagonist, controlled diarrhoea in five of six patients studied. This drug may be a useful advance in the symptomatic treatment of the carcinoid syndrome.
